Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login


Adding New Treatment to Standard Chemo

  • April 01 2014

    Share |
    Adding New Treatment to Standard Chemo

    Docetaxel is a standard chemotherapy treatment relied on by many lung cancer patients. But might these patients’ survival rates improve if a new drug is added to their treatment regimen? In this clinical trial, half of participants will receive standard of care docetaxel, and half will receive docetaxel plus a drug called ganetespib. Ganetespib works by blocking Hsp90, a type of protein in the body that cancer cells rely on for growth.


    This clinical trial is open to patients with stage IIIB or IV non-small cell lung cancer (adenocarcinoma or large cell carcinoma), whose disease continued advancing after a first round of chemotherapy or targeted treatment.

    Learn more about eligibility and other details of this clinical trial >


Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2018 Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.